1-CD20 single chain variable antibody-apolipoprotein-A1 fusion protein (Abionyx)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Name1-CD20 single chain variable antibody-apolipoprotein-A1 fusion protein (Abionyx)
Drug Alias Name1-CD20 scFv7apoA-I ATRA-ND (Lypro)1-CD20 single chain variable antibody-apolipoprotein-A1 fusion protein (Lypro)ATRA-ND (Lypro)all trans retinoic acid-NanoDisks (Cerenis Therapeutics)1-CD20 scFv7apoA-I ATRA-ND (Cerenis Therapeutics) +[8] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionApolipoprotein A-I modulatorsB-lymphocyte antigen CD20 modulators
TargetsB-lymphocyte antigen CD20Apolipoprotein A-I
Therapy Area/IndicationsLymphoma, Mantle-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesLypro Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLypro Biosciences IncAbionyx Pharma SA
Active IndicationsN/A
Inactive IndicationsLymphoma, Mantle-Cell

Other Information

ATC CodeN/A
Related LinksN/A